Summit Therapeutics
Develops Akeso-origin ivonescimab through multinational late-stage oncology trials.
$13.71
After-hours close+0.00 (+0.03%)
At close$13.71(−4.33%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | −$0.28 | — | — |
| Jul 2026 | −$0.27 | −$0.28 | −2.0% |
| Apr 2026 | −$0.33 | −$0.24 | +27.3% |
| Feb 2026 | −$0.10 | −$0.29 | −182.5% |
| Oct 2025 | −$0.18 | −$0.31 | −76.4% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Dec 2019 | |||
| Jul 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Apr 2018 | |||
| Dec 2017 | |||
| Aug 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| May 2016 | |||
| Dec 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 19, 2026 | −$0.28 | — | — | $71.4K | — | — |
| Jul 23, 2026 | −$0.27 | −$0.28 | −2.0% | $113.8K | — | — |
| Apr 30, 2026 | −$0.33 | −$0.24 | +27.3% | $54.4K | — | — |
| Feb 23, 2026 | −$0.10 | −$0.29 | −182.5% | $56.8M | — | — |
| Oct 20, 2025 | −$0.18 | −$0.31 | −76.4% | $76.5M | — | — |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 11, 2025 | ||||||
| May 1, 2025 | ||||||
| Feb 24, 2025 | ||||||
| Oct 30, 2024 | ||||||
| Aug 6, 2024 | ||||||
| May 1, 2024 | ||||||
| Feb 20, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 9, 2023 | ||||||
| May 11, 2023 | ||||||
| Mar 9, 2023 | ||||||
| Nov 9, 2022 | ||||||
| Aug 11, 2022 | ||||||
| May 11, 2022 | ||||||
| Mar 17, 2022 | ||||||
| Nov 15, 2021 | ||||||
| Aug 11, 2021 | ||||||
| May 17, 2021 | ||||||
| Mar 17, 2021 | ||||||
| Nov 16, 2020 | ||||||
| Sep 29, 2020 | ||||||
| Jun 3, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Dec 17, 2019 | ||||||
| Jul 31, 2019 | ||||||
| Jun 12, 2019 | ||||||
| Mar 27, 2019 | ||||||
| Dec 11, 2018 | ||||||
| Sep 20, 2018 | ||||||
| Jun 5, 2018 | ||||||
| Apr 13, 2018 | ||||||
| Dec 6, 2017 | ||||||
| Aug 31, 2017 | ||||||
| Jun 14, 2017 | ||||||
| Mar 29, 2017 | ||||||
| Dec 15, 2016 | ||||||
| Sep 8, 2016 | ||||||
| Jun 2, 2016 | ||||||
| May 10, 2016 | ||||||
| Dec 17, 2015 | ||||||
| Aug 27, 2015 | ||||||